Molina Healthcare vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Long Beach CA Medicaid managed care (NYSE: MOH) ~$38.7B FY2024 revenue; 5.7M members in 19 states, Medicaid redetermination management, D-SNP growth competing with Centene and Elevance.
About
Molina Healthcare, Inc. is a Long Beach, California-based managed care organization — publicly traded on the New York Stock Exchange (NYSE: MOH) as an S&P 500 Health Care component — providing Medicaid, Medicare, and Marketplace (Affordable Care Act exchange) health insurance through state-contracted managed care plans to approximately 5.7 million low-income, elderly, and disabled members across 19 states, with revenues generated primarily from per-member-per-month (PMPM) capitation payments received from state Medicaid agencies and CMS Medicare programs. In fiscal year 2024, Molina Healthcare reported revenues of approximately $38.7 billion — primarily from Medicaid capitation payments from state Medicaid agencies that contract with Molina to administer benefits for enrolled beneficiaries — generating net income impacted by elevated medical costs in the Marketplace segment as post-COVID health utilization normalization drove medical loss ratios above expectations. CEO Joseph Zubretsky's strategy of disciplined Medicaid contract renewal and Medicaid redetermination management positioned Molina for the 2023-2024 Medicaid unwinding — the federal pandemic-era continuous enrollment requirement expiration required states to redetermine eligibility for all Medicaid enrollees, with Molina proactively assisting ineligible members transition to Marketplace plans to retain the relationship. Molina's marketplace business expansion (Affordable Care Act exchange plans in new states and existing markets) provides enrollment growth offsetting Medicaid membership losses from redetermination, while Medicare Dual Eligible Special Needs Plans (D-SNPs — serving members eligible for both Medicaid and Medicare) represent the highest-growth and highest-margin Molina product line.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.